Regulatory & Legal

Denarius Metals solidifies its Zancudo gold-silver project in Colombia by filing a key technical report, validating a major resource update.

Following PwC's resignation, the private credit firm's move to MNP signals a new chapter in its financial governance as it streamlines operations.

In a fierce biotech talent war, Senti Bio's new equity grant for a key hire signals a strategic push for its gene therapy pipeline amid market volatility.

With a massive capital raise and rapid microreactor progress, NANO Nuclear is positioning itself to power the AI boom and lead a new nuclear renaissance.

An executive order accelerates moving cannabis to Schedule III, promising massive tax breaks for businesses but leaving advocates wanting more federal reform.

Facing financial headwinds, Celularity lands a critical $12M from a top investor to push its ambitious anti-aging and regenerative therapies forward.

A new national scholarship champions medical integrity, yet its founder recently settled a major False Claims Act case, raising complex questions.

A Minnesota startup has secured major funding to advance its bioelectronic device aimed at the brain's waste clearance system for treating CNS disorders.

A training intensive promises to turn teachers into six-figure consultants. But behind the bold claims, some educators question the high-stakes business model.

An expert shares urgent year-end tips on charitable giving, portfolio rebalancing, and college savings to maximize benefits before new tax laws take effect.

A new Commerce Dept. ruling hikes duties on Chinese mobile access equipment to nearly 70%, a win for U.S. firms but a blow to importers and buyers.

A simple, low-cost heart pill may hold the key to treating Alzheimer's and kidney disease. CardioPharma is now funding research to unlock its potential.

Millions struggle to swallow pills. Azurity's new FDA-approved liquid hypertension drug, Javadin, offers a ready-to-use solution for better adherence.

Medical cannabis firm Crucial Innovations retains FOCUS Capital Partners, signaling a push for institutional investment and a potential 2026 US listing.

A new report projects a staggering $47T cost from chronic illness by 2039. Experts say prevention and innovation could save trillions and 13.5M lives.

Syra Health appoints Gregory R. Alexander as CEO, banking on his military discipline and record of scaling healthcare firms to drive its next growth phase.

Precious metals soar in 2025, with silver's 128% surge fueled by geopolitical turmoil, economic fears, and a booming demand from green tech and AI.

Picard Medical rings the NYSE bell, but its stock's volatile journey reflects the high-stakes gamble on its next-generation artificial heart technology.

Leveraging a fleet of vintage F-104 jets, Starfighters Space raises $40M and goes public, aiming to disrupt the small satellite launch market.

With trial data showing an average 23% body weight loss, Novo Nordisk's new combination drug CagriSema could usher in a powerful new era for medicine.